PBMC inflammation assay
This assay is under development and will be available soon. The stimuli and detected response may be altered, however as an idea of the protocol: human peripheral blood mononuclear cells (PBMCs) will be presented with beads coated in CD3 & CD28, and exposed to IL-23 in the medium, to induce an inflammatory response, detected as an increase in IL-17 secretion. Your compound will be tested for its ability to inhibit this inflammatory response, measured as an inhibition of IL-17 release. Cellular viability will also be assessed, as a measure of general compound cytotoxicity.